Cargando…

Elevated XIAP expression alone does not confer chemoresistance

BACKGROUND: In various tumour types, elevated expression of the X-linked inhibitor of apoptosis protein (XIAP) has been observed and XIAP targeting in diverse tumour entities enhanced the susceptibility to chemotherapeutic agents. Therefore, XIAP has been described and reviewed repeatedly as a chemo...

Descripción completa

Detalles Bibliográficos
Autores principales: Seeger, J M, Brinkmann, K, Yazdanpanah, B, Haubert, D, Pongratz, C, Coutelle, O, Krönke, M, Kashkar, H
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2883704/
https://www.ncbi.nlm.nih.gov/pubmed/20485285
http://dx.doi.org/10.1038/sj.bjc.6605704
_version_ 1782182274298544128
author Seeger, J M
Brinkmann, K
Yazdanpanah, B
Haubert, D
Pongratz, C
Coutelle, O
Krönke, M
Kashkar, H
author_facet Seeger, J M
Brinkmann, K
Yazdanpanah, B
Haubert, D
Pongratz, C
Coutelle, O
Krönke, M
Kashkar, H
author_sort Seeger, J M
collection PubMed
description BACKGROUND: In various tumour types, elevated expression of the X-linked inhibitor of apoptosis protein (XIAP) has been observed and XIAP targeting in diverse tumour entities enhanced the susceptibility to chemotherapeutic agents. Therefore, XIAP has been described and reviewed repeatedly as a chemoresistance factor in different tumour entities. However, rather than being an adverse prognostic marker, recent data suggest that elevated XIAP expression may be associated with a favourable clinical outcome. These somewhat conflicting findings, and the fact that in early studies XIAP suppressed apoptosis only when expressed transiently at levels far in excess of its physiological concentration, argue that the function of XIAP as an anti-apoptotic factor in tumour cells is both more complex and diverse than previously appreciated. METHODS: To better understand the impact of long-term elevated XIAP expression on resistance to chemotherapy, we generated cell lines stably overexpressing XIAP. The role of mitochondria was examined by stable expression of Bcl2 or stable knockdown of second mitochondria-derived activator of caspase (SMAC) in combination with up- or downregulation of XIAP expression. RESULTS: Our data show that long-term expression of XIAP at concentrations comparable to that in tumour cells (two- to five-fold increase) resulted in little or no resistance towards chemotherapeutic drugs. The XIAP overexpression only in conjunction with stable knockdown of a single XIAP-antagonising factor such as SMAC resulted in severe resistance to cytostatic agents demonstrating XIAP as a potent chemoresistance factor only in cells lacking functional XIAP regulatory circuits. CONCLUSION: Our results demonstrated that elevated XIAP expression alone cannot serve as a predictive marker of chemoresistance. Our data suggest that in order to predict the impact of XIAP on chemosusceptibility for a given tumour entity, the expression levels and functional states of all XIAP modulators need to be taken into account.
format Text
id pubmed-2883704
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-28837042011-06-08 Elevated XIAP expression alone does not confer chemoresistance Seeger, J M Brinkmann, K Yazdanpanah, B Haubert, D Pongratz, C Coutelle, O Krönke, M Kashkar, H Br J Cancer Translational Therapeutics BACKGROUND: In various tumour types, elevated expression of the X-linked inhibitor of apoptosis protein (XIAP) has been observed and XIAP targeting in diverse tumour entities enhanced the susceptibility to chemotherapeutic agents. Therefore, XIAP has been described and reviewed repeatedly as a chemoresistance factor in different tumour entities. However, rather than being an adverse prognostic marker, recent data suggest that elevated XIAP expression may be associated with a favourable clinical outcome. These somewhat conflicting findings, and the fact that in early studies XIAP suppressed apoptosis only when expressed transiently at levels far in excess of its physiological concentration, argue that the function of XIAP as an anti-apoptotic factor in tumour cells is both more complex and diverse than previously appreciated. METHODS: To better understand the impact of long-term elevated XIAP expression on resistance to chemotherapy, we generated cell lines stably overexpressing XIAP. The role of mitochondria was examined by stable expression of Bcl2 or stable knockdown of second mitochondria-derived activator of caspase (SMAC) in combination with up- or downregulation of XIAP expression. RESULTS: Our data show that long-term expression of XIAP at concentrations comparable to that in tumour cells (two- to five-fold increase) resulted in little or no resistance towards chemotherapeutic drugs. The XIAP overexpression only in conjunction with stable knockdown of a single XIAP-antagonising factor such as SMAC resulted in severe resistance to cytostatic agents demonstrating XIAP as a potent chemoresistance factor only in cells lacking functional XIAP regulatory circuits. CONCLUSION: Our results demonstrated that elevated XIAP expression alone cannot serve as a predictive marker of chemoresistance. Our data suggest that in order to predict the impact of XIAP on chemosusceptibility for a given tumour entity, the expression levels and functional states of all XIAP modulators need to be taken into account. Nature Publishing Group 2010-06-08 2010-05-18 /pmc/articles/PMC2883704/ /pubmed/20485285 http://dx.doi.org/10.1038/sj.bjc.6605704 Text en Copyright © 2010 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Translational Therapeutics
Seeger, J M
Brinkmann, K
Yazdanpanah, B
Haubert, D
Pongratz, C
Coutelle, O
Krönke, M
Kashkar, H
Elevated XIAP expression alone does not confer chemoresistance
title Elevated XIAP expression alone does not confer chemoresistance
title_full Elevated XIAP expression alone does not confer chemoresistance
title_fullStr Elevated XIAP expression alone does not confer chemoresistance
title_full_unstemmed Elevated XIAP expression alone does not confer chemoresistance
title_short Elevated XIAP expression alone does not confer chemoresistance
title_sort elevated xiap expression alone does not confer chemoresistance
topic Translational Therapeutics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2883704/
https://www.ncbi.nlm.nih.gov/pubmed/20485285
http://dx.doi.org/10.1038/sj.bjc.6605704
work_keys_str_mv AT seegerjm elevatedxiapexpressionalonedoesnotconferchemoresistance
AT brinkmannk elevatedxiapexpressionalonedoesnotconferchemoresistance
AT yazdanpanahb elevatedxiapexpressionalonedoesnotconferchemoresistance
AT haubertd elevatedxiapexpressionalonedoesnotconferchemoresistance
AT pongratzc elevatedxiapexpressionalonedoesnotconferchemoresistance
AT coutelleo elevatedxiapexpressionalonedoesnotconferchemoresistance
AT kronkem elevatedxiapexpressionalonedoesnotconferchemoresistance
AT kashkarh elevatedxiapexpressionalonedoesnotconferchemoresistance